Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

114.81 -0.83 (-0.72%)
Official Closing Price Updated: 7:00 PM EDT, Oct 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis Ag ADR

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall?
Crispr is planning to begin a registrational test in the first quarter of 2022. 
Via Investor's Business Daily
eFFECTOR Therapeutics Stock Gains On Encouraging Preclinical Zotatifin Data In Breast Cancer
eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zotatifin in... 
Via Benzinga
Cannabis Movers & Shakers: TOCC, 1933 Industries, Iter Investments, Greenlane
Former Tilray Exec Steven Yoo Named Texas Original Compassionate Cultivation's New CFO Texas medical cannabis provider,&n... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
September Update: The Conservative Pot Stocks Index Continued To Outperform
Reticent about investing in the seed-to-sale sector? Perhaps you should consider investing in more conservative cannabis-related companies, which have lost less YTD. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Death Cross Looms Over Novartis Investors
If history is any guide, there may be trouble ahead for shares of Novartis(NYSE:NVS). A so-called "death cross" has formed on its chart and, not surprisingly, this could... 
Via Benzinga
What may be behind achy, tired, or burning eyes? Dry eye disease may be the culprit.
(BPT) - Sponsored by Novartis Pharmaceuticals Corporation. 
Via Brandpoint
Exposures COVID-19
A Bit Of A Recovery
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week. 
Via Talk Markets
Novartis Posts New Data Reinforcing Efficacy, Convenience Of Cosentyx Autoinjector In Psoriasis
Novartis AG (NYSE: NVS) announced data from an international Phase 3b study of Cosentyx (secukinumab) in plaque psoriasis. Data showed that treatment with Cosentyx... 
Via Benzinga
This Potential Indication Could Be a Winner for Novartis
The U.S. Food and Drug Administration accepted Novartis' filing for tislelizumab to treat esophageal cancer. 
Via The Motley Fool
Exposures Product Safety
Green Hygienics Holdings To Raise $100M Via Green Bond Offering
Hemp company Green Hygienics Holdings Inc. (OTCQB:GRYN) is ... 
Via Benzinga
A Day Of Huge Market Moves
It was a day of huge market moves and several reporting companies. Trudeau won but did not get a parliamentary majority. 
Via Talk Markets
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition
Novartis AG (NYSE: NVS) has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its... 
Via Benzinga
Pharma, Tech and Finance
Good news on some drugs was not enough to boost stock markets. 
Via Talk Markets
Why Did Deutsche Bank Downgrade This Big Pharma Stock?
Deutsche Bank has downgraded Novartis AG (NYSE: NVS) to Sell from Hold with a price target of CHF 70, down from CHF 80. Analyst Emmanuel... 
Via Benzinga
Novartis' Kisqali Combo Therapy Extends Survival By One Year In Breast Cancer Patients
Novartis AG (NYSE: NVS) announced results of the final overall survival (OS) analysis of Phase 3 MONALEESA-2 study, which evaluated Kisqali (ribociclib) in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2021
Upgrades For Methanex Corp (NASDAQ: 
Via Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Exposures Product Safety
Visualizing the World’s Biggest Pharmaceutical Companies
Some of the world’s biggest pharmaceutical companies have played a central role in the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life
Novartis AG (NYSE: NVS) is building the case for its radioligand therapy, 177Lu-PSMA-617. With positive Phase 3 primary endpoint data in the bag, Novartis at the European... 
Via Benzinga
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-... 
Via Benzinga
Better Pharmaceutical Stock: Apellis or Novartis?
The pharmaceutical industry is expected to remain in the limelight as companies race to develop new medicines catering to mild diseases and critical ailments. 
Via Talk Markets
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
CureVac BV has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. 
Via Talk Markets
Exposures COVID-19
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would... 
Via Benzinga
Exposures COVID-19
Why Regenxbio Stock Is Way Up Today
American biopharmaceutical giant AbbVie wants access to Regenexbio's gene therapy for macular degeneration. 
Via The Motley Fool
ADHD Drug Developer Cingulate Plans NASDAQ Debut
Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Why Did Wedbush Downgrade Xoma?
Wedbush has cut XOMA Corporation (NASDAQ: XOMA) to neutral from outperform and lowered its price target to $22 from $41. Analyst Liana Moussatos notes ... 
Via Benzinga
Novartis Stops Iscalimab Trial In Kidney Transplant Patients
Novartis AG (NYSE: NVS) has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients. The decision follows interim data that showed iscalimab was... 
Via Benzinga
Price Over Earnings Overview: Novartis
Looking into the current session, Novartis Inc. (NYSE:NVS) is trading at $92.23, after a 0.45% drop. Over the past month, the stock decreased by 0.02%, but over the... 
Via Benzinga
The Rising Delta Variant
China is not only cracking down on kiddie playtime. It also is absorbing bankruptcy claims from real estate developer Evergrande. 
Via Talk Markets
Topics Bankruptcy
Exposures Financial Legal
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.